Cases & Deals

Share

Astellas acquires Iveric bio

April 2023

Clients Astellas Pharma Inc.

Jones Day is advising Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.

Upon completion of the transaction, Iveric will no longer be traded or listed on any public securities exchange. The transaction is expected to close in the third quarter of 2023, subject to customary closing conditions.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.